ASH 2024
SAN DIEGO
Gilead & Kite at ASH 2024
At ASH 2024, we are excited to share new data across different therapies and indications, soliditying our goal to bring the promise of cell therapy to as many eligible patients as possible. Learn more about the cell therapy sponsored and supported/collaborative studies below.
Some of the abstracts below refer to therapies and/or indications that are investigational and their satety and efficacy have not been established.
Real-Word Early Outcomes of Second-Line Axi-Cel Therapy in Patients with R/R LBCL
Real-world Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axi-cel for R/R LBCL in the US: A CIBMTR Report
Predictors of Early Safety Outcomes with Axi-Cel in Patients with R/R LBCL
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
5-Year Follow-up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in Patients With R/R Indolent Non-Hodgkin Lymphoma
Early MRD detection after CAR-T Associated with Poor Outcome in in Patients with Large B-Cell Lymphoma*
Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma
KITE-753: An Autologous Rapid Manufactured Anti-CD19/ CD20 CAR-T Product for the Treatment of B-cell Malignancies
The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non- Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study)
Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in ZUMA-3 Pivotal Study
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
Five-Year Outcomes of Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated With Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety With 34-Month Median Follow-up
Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) by High-Risk Features and Prior Treatments: Updated Evidence From the CIBMTR® Registry
Mutational Landscape and Depth of Response In Patients With Acute Myeloid Leukemia (AML) Treated With Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo
Impact of mutational landscape and CD47 levels in the magrolimab + azacitidine vs placebo + azacitidine trial in patients with untreated higher risk myelodysplastic syndrome
Effects of Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics in Pediatric Acute Myeloid Leukemia Patient Derived Xenograft Models
Anti-CD117 plus anti-SIRPa or Fc-silenced anti-CD47 enables hematopoietic stem cell depletion and syngeneic engraftment without development of severe anemia
Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database
In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized by Overexpression of GATA3 Transcript
A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronextamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma
Short-term Costs Associated With Outpatient Use of Axicabtagene Ciloleucel in Second-line Relapsed/ Refractory Large B-cell Lymphoma Based on ZUMA-24 Clinical Trial
Real-World Interim PET/CT Scan Use During Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)